Bristol Myers Squibb (BMY) FCF Margin (2009 - 2026)

Bristol Myers Squibb (BMY) has reported FCF Margin for 18 consecutive years, with 23.8% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin fell 518.0% year-over-year to 23.8% in Q2 2026; TTM through Jun 2026 was 23.26%, a 730.0% decrease from a year earlier, with the FY2025 full-year figure at 26.65%, down 221.0% from the prior year.
• FCF Margin was 23.8% for Q2 2026 at Bristol Myers Squibb, up from 6.59% in the prior quarter.
• Over five years, FCF Margin peaked at 49.02% in Q3 2025 and troughed at 6.59% in Q1 2026.
• A 5-year average of 26.03% and a median of 24.88% in 2026 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 1207 bps in 2025, down 2007 bps in 2025.
• Over 5 years, FCF Margin stood at 25.95% in 2022, then jumped by 32 bps to 34.17% in 2023, then retreated by 4 bps to 32.9% in 2024, then sank by 61 bps to 12.83% in 2025, then soared by 86 bps to 23.8% in 2026.
• The last three FCF Margin figures came in at 23.8% (Q2 2026), 6.59% (Q1 2026), and 12.83% (Q4 2025), per Business Quant data.